Disease-modifying Drugs in Osteoarthritis: Current Understanding and Future Therapeutics.

Disease-modifying Drugs in Osteoarthritis: Current Understanding and Future Therapeutics. Expert Opin Emerg Drugs. 2018 Nov 12;: Authors: Oo WM, Yu SC, Daniel MS, Hunter DJ Abstract INTRODUCTION: Osteoarthritis (OA) is a leading cause of pain and disability among adults with a current prevalence of around 15% and a predicted prevalence of 35% in 2030 for symptomatic OA. It is increasingly recognized as a heterogeneous multi-faceted joint disease with multi-tissue involvement of varying severity. Current therapeutic regimens for OA are only partially effective and often have significant associated toxicities. There are no disease-modifying drugs approved by the regulatory bodies. Areas covered: We reviewed the opportunities within key OA pathogenetic mechanism: cartilage catabolism/anabolism, pathological remodelling of subchondral bone and synovial inflammation to identify targeted disease-modifying osteoarthritis drugs (DMOADs), based on compounds currently in Phase II and III stages of clinical development in which x-ray and/or MRI was used as the structural outcome with/without symptomatic outcomes according to regulatory requirements. Expert opinion: Given the heterogeneity of the OA disease process and complex overlapping among these phenotypes, a "one size fits all" approach used in most clinical trials would unlikely be practical and equally effective in all patients, as well as in all anatomical OA sites. On the other hand, i...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research